ArticleThe World Allergy Organization journal2015
Intralymphatic immunotherapy.
Article in The World Allergy Organization journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02665754 (The Efficacy and Adverse Effect of Intralymphatic Immunotherapy With Tyrosine S®, Allergen Extract for Immunotherapy, in Patients With Allergic Rhinitis Induced by House Dust Mite, Dog, and Cat Allergen), which is not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Efficacy and Adverse Effect of Intralymphatic Immunotherapy With Tyrosine S®, Allergen Extract for Immunotherapy, in Patients With Allergic Rhinitis Induced by House Dust Mite, Dog, and Cat Allergen
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of intralymphatic immunotherapy for allergic rhinitis: an overview of systematic reviews and meta analyses.Frontiers in medicine · 2025Pooled it
- Defined distribution and features of lymph node therapies enable recruitment and manipulation of antigen-specific T cell response.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Emerging strategies in lymph node-targeted nano-delivery systems for tumor immunotherapy.Essays in biochemistry · 2025Review
- Intranodal Injection of Immune Activator Demonstrates Antitumor Efficacy in an Adjuvant Approach.Vaccines · 2024Article
- Confronting allergies: strategies for combating pollution and safeguarding our health.Frontiers in allergy · 2024Review
- Lymph node targeting for immunotherapy.Immuno-oncology technology · 2023Review
- Delivery route considerations for designing antigen-specific biomaterial strategies to combat autoimmunity.Advanced nanobiomed research · 2023Article
- mRNA-From COVID-19 Treatment to Cancer Immunotherapy.Biomedicines · 2023Review
- Formulation and Delivery Technologies for mRNA Vaccines.Current topics in microbiology and immunology · 2022Article
- mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients.Vaccines · 2021Review
- Bee Venom Immunotherapy: Current Status and Future Directions.Clinical reviews in allergy & immunology · 2020Review
- Development of a novel murine model of lymphatic metastasis.Clinical & experimental metastasis · 2020Article
- Intranodal administration of mRNA encoding nucleoprotein provides cross-strain immunity against influenza in mice.Journal of translational medicine · 2019Article
- Harnessing the lymph node microenvironment.Current opinion in organ transplantation · 2018Review
- Allergen-specific intralymphatic immunotherapy in human and animal studies.Asia Pacific allergy · 2017Review
- [Innovative forms of specific immunotherapy].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2017Review
- Biodistribution and Efficacy of Human Adipose-Derived Mesenchymal Stem Cells Following Intranodal Administration in Experimental Colitis.Frontiers in immunology · 2017Article
- Intralymphatic Administration of Adipose Mesenchymal Stem Cells Reduces the Severity of Collagen-Induced Experimental Arthritis.Frontiers in immunology · 2017Article
- Personalized Medicine in Allergic Asthma: At the Crossroads of Allergen Immunotherapy and "Biologicals".Frontiers in pediatrics · 2017Review
- Reprogramming the Local Lymph Node Microenvironment Promotes Tolerance that Is Systemic and Antigen Specific.Cell reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gold Standard allergen-specific immunotherapy is associated with low efficacy because it requires either many subcutaneous injections of allergen or even more numerous sublingual allergen administrations to achieve amelioration of symptoms. Intralymphatic vaccination can maximize immunogenicity and hence efficacy. We and others have demonstrated that as few as three low dose intralymphatic allergen administrations are sufficient to effectively alleviate symptoms. Results of recent prospective and controlled trials suggest that this strategy may be an effective form of allergen immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.